Search Results - "TOFE, SANTIAGO"

Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial by Rosenstock, Julio, Frías, Juan P, Rodbard, Helena W, Tofé, Santiago, Sears, Emmalee, Huh, Ruth, Fernández Landó, Laura, Patel, Hiren

“…IMPORTANCE: Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist used for the treatment of type 2…”
Get full text

Ultrasound-Guided Ethanol Percutaneous Ablation Versus Rescue Surgery in Patients With Locoregional Recurrence of Papillary Thyroid Cancer by Tofé, Santiago, Argüelles, Iñaki, Álvarez, Cristina, Tofé, Álvaro, Repetto, Alessandra, Barceló, Antonia, Pereg, Vicente

“…Neck recurrence of papillary thyroid cancer (PTC) is frequently detected after initial surgery. The management of these lesions may include rescue surgery (RS)…”
Get full text

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program by Nicholls, Stephen J, Tofé, Santiago, le Roux, Carel W, D'Alessio, David A, Wiese, Russell J, Pavo, Imre, Brown, Katelyn, Weerakkody, Govinda J, Zeytinoglu, Meltem, Romera, Irene C

“…Metabolic syndrome is characterized as the co-occurrence of interrelated cardiovascular risk factors, including insulin resistance, hyperinsulinemia, abdominal…”
Get full text

Age-standardized incidence, mortality rate, and trend changes of thyroid cancer in the Balearic Islands during the 2000-2020 period: a population-based study by Tofé, Santiago, Argüelles, Iñaki, Forteza, Ana, Álvarez, Cristina, Repetto, Alessandra, Masmiquel, Luis, Rodríguez, Irene, Losada, Eladio, Sukunza, Nuria, Cabrer, María, Sifontes, Mildred, Del Mar Del Barrio, María, Barceló, Antonia, Tofé, Álvaro, Pereg, Vicente

“…Global thyroid cancer (TC) incidence is growing worldwide, but great heterogenicity exists among published studies, and thus, population-specific…”
Get full text

Real‐world GLP‐1 RA therapy in type 2 diabetes: A long‐term effectiveness observational study by Tofé, Santiago, Argüelles, Iñaki, Mena, Elena, Serra, Guillermo, Codina, Mercedes, Urgeles, Juan Ramón, García, Honorato, Pereg, Vicente

“…Summary Aims To evaluate in a real‐world setting the effectiveness and tolerability of available GLP‐1 RA drugs in patients with type 2 diabetes after a…”
Get full text

Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3) by UMPIERREZ, Guillermo, POVEDANO, Santiago Tofé, MANGHI, Federico Pérez, SHURZINSKE, Linda, PECHTNER, Valeria

“…Compare the efficacy and safety of monotherapy with dulaglutide, a once-weekly GLP-1 receptor agonist, to metformin-treated patients with type 2 diabetes. The…”
Get full text

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial by Dungan, Kathleen M, Dr, Povedano, Santiago Tofé, MD, Forst, Thomas, MD, González, José G González, Prof, Atisso, Charles, PhD, Sealls, Whitney, PhD, Fahrbach, Jessie L, MD

“…Summary Background Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients…”
Get full text

Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity by Nicolau, Joana, Pujol, Antelm, Tofé, Santiago, Bonet, Aina, Gil, Apolonia

“…•Emotional eating is highly frequent among patients with obesity.•Emotional eating has a negative impact on weight loss and maintenance.•Semaglutide improves…”
Get full text

Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison by Osumili, Beatrice, Fan, Ludi, Paik, Jim S., Pantalone, Kevin M., Ranta, Kari, Sapin, Hélène, Tofé, Santiago

“…To compare the efficacy and safety of tirzepatide 5, 10 and 15 mg with subcutaneous semaglutide 0.5 mg as second-line treatment for adults with type 2 diabetes…”
Get full text

Effects of weight stigma on BMI and inflammatory markers among people living with obesity by Nicolau, Joana, Tofé, Santiago, Bonet, Aina, Sanchís, Pilar, Pujol, Antelm, Ayala, Luisa, Gil, Apolonia, Masmiquel, Lluís

“…•BMI positively correlates with the presence of weight stigma.•The presence of weight stigma does not exert a significant influence on weight…”
Get full text

Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain by Norrbacka, Kirsi, Sicras-Mainar, Antoni, Lebrec, Jeremie, Artime, Esther, Díaz, Silvia, Tofé-Povedano, Santiago, Hernández, Ignacio, Romera, Irene

“…Introduction This study aimed to describe utilization patterns, persistence, resource utilization and costs in patients with type 2 diabetes mellitus…”
Get full text

Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects by Vázquez, Luis A., Tofé-Povedano, Santiago, Bellido-Guerrero, Diego, Botella-Serrano, Marta, Soto-González, Alfonso, Mezquita-Raya, Pedro, Delgado, Elías, Fajardo-Montañana, Carmen, Morales-Portillo, Cristóbal, Causanilles, Ana, Rubio-de Santos, Miriam, Romera, Irene, Jódar-Gimeno, Esteban

“…Tirzepatide is a novel antidiabetic medication a single-molecule, agonist to the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1…”
Get full text

757-P: Near-Normoglycemia and Insulin Regression Induced by Tirzepatide in Basal Insulin–Treated Type 2 Diabetes by Rosenstock, Julio, Tofe, Santiago, Wysham, Carol H, Thieu, Vivian, Kiljanski, Jacek I, Lee, Clare, Wang, Hui, Patel, Hiren

“…Introduction & Objective: In the SURPASS-6 trial, addition of tirzepatide (TZP) to basal insulin glargine U100 in participants with inadequately controlled…”
Get full text

743-P: Clinical Factors Associated with Insulin Regression When Adding Tirzepatide in Basal Insulin–Treated Type 2 Diabetes by Wysham, Carol H, Rosenstock, Julio, Tofe, Santiago, Thieu, Vivian, Kiljanski, Jacek I, Lee, Clare, Wang, Hui, Patel, Hiren

“…Introduction & Objective: In the SURPASS-6 trial, tirzepatide (TZP) added to basal insulin glargine U100 significantly improved HbA1c and body weight in…”
Get full text

743-P: Effect of Once-Weekly TZP on Glycemic Control by Baseline Age in Patient Subpopulations from the SURPASS Trials by WYSHAM, CAROL H., TOFE, SANTIAGO, SAPIN, HELENE, MALIK, RALEIGH, NEFF, LISA M.

“…Tirzepatide (TZP) is a dual GIP and GLP-1 receptor agonist developed for the treatment of patients with type 2 diabetes (T2D) . The SURPASS clinical trials…”
Get full text

73-LB: Tirzepatide 5, 10, and 15 mg vs Injectable Semaglutide 0.5 mg for the Treatment of Type 2 Diabetes—An Indirect Treatment Comparison by PANTALONE, KEVIN M., TOFE, SANTIAGO, FAN, LUDI, PAIK, JIM S., RANTA, KARI T., SAPIN, HELENE, OSUMILI, BEATRICE

“…Semaglutide (sema) 0.5 mg is part of type 2 diabetes (T2D) standard of care as initial maintenance dose. While there has been a study conducted on TZP and sema…”
Get full text

24‐Hour and Nighttime Blood Pressures in Type 2 Diabetic Hypertensive Patients Following Morning or Evening Administration of Olmesartan by Tofe Povedano, Santiago, Garcia De La Villa, Bernardo

“…Ambulatory blood pressure monitoring (ABPM) allows determining of the nocturnal blood pressure fall (NBPF). An NBPF below 10% (nondipper pattern) has been…”
Get full text

An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain by Tofé, Santiago, Argüelles, Iñaki, Mena, Elena, Serra, Guillermo, Codina, Mercedes, Urgelés, Juan Ramón, García, Honorato, Pereg, Vicente

“…•First Real-World study to present data on clinical effectiveness for the comparison of Dulaglutide vs subcutaneous Semaglutide in routine clinical…”
Get full text

750-P: “SURPASS(ing)” an Era of Basal-Bolus Insulin Therapy—Tirzepatide vs. Insulin Lispro TID Added-on to Poorly Controlled Basal Insulin-Treated in Type 2 Diabetes by ROSENSTOCK, JULIO, FRIAS, JUAN P., RODBARD, HELENA W., TOFE, SANTIAGO, SEARS, EMMALEE J., HUH, RUTH, FERNANDEZ LANDO, LAURA, PATEL, HIREN

“…Tirzepatide (TZP) is a once weekly GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes (T2D). In this 52-wk open-label, multicenter, Phase 3b…”
Get full text

Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis by Tofé, Santiago, Moreno, José C, Máiz, Luis, Alonso, Milagros, Escobar, Héctor, Barrio, Raquel

“…Objective: To evaluate insulin-secretion kinetics and insulin sensitivity in cystic fibrosis (CF) patients with normal glucose tolerance (CF-NGT), impaired…”
Get full text